Cargando…

Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus

Antitumor efficacy of systemically administered oncolytic adenoviruses (OAdv) is limited due to diverse factors such as liver sequestration, neutralizing interactions in blood, elimination by the immune system, and physical barriers in tumors. It is therefore of clinical relevance to improve OAdv bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreno, R., Rojas, L. A., Villellas, Felip Vilardell, Soriano, Vanessa Cervera, García-Castro, J., Fajardo, C. A., Alemany, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525077/
https://www.ncbi.nlm.nih.gov/pubmed/28781596
http://dx.doi.org/10.1155/2017/3615729
_version_ 1783252579962060800
author Moreno, R.
Rojas, L. A.
Villellas, Felip Vilardell
Soriano, Vanessa Cervera
García-Castro, J.
Fajardo, C. A.
Alemany, R.
author_facet Moreno, R.
Rojas, L. A.
Villellas, Felip Vilardell
Soriano, Vanessa Cervera
García-Castro, J.
Fajardo, C. A.
Alemany, R.
author_sort Moreno, R.
collection PubMed
description Antitumor efficacy of systemically administered oncolytic adenoviruses (OAdv) is limited due to diverse factors such as liver sequestration, neutralizing interactions in blood, elimination by the immune system, and physical barriers in tumors. It is therefore of clinical relevance to improve OAdv bioavailability and tumor delivery. Among the variety of tumor-targeting strategies, the use of stem cells and specifically bone marrow-derived mesenchymal stem cells (BM-MSCs) is of particular interest due to their tumor tropism and immunomodulatory properties. Nonetheless, the invasive methods to obtain these cells, the low number of MSCs present in the bone marrow, and their restricted in vitro expansion represent major obstacles for their use in cancer treatments, pointing out the necessity to identify an alternative source of MSCs. Here, we have evaluated the use of menstrual blood-derived mesenchymal stem cells (MenSCs) as cell carriers for regional delivery of an OAdv in the tumor. Our results indicate that MenSCs can be isolated without invasive methods, they have an increased proliferation rate compared to BM-MSCs, and they can be efficiently infected with different serotype 5-based capsid-modified adenoviruses, leading to viral replication and release. In addition, our in vivo studies confirmed the tumor-homing properties of MenSCs after regional administration.
format Online
Article
Text
id pubmed-5525077
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-55250772017-08-06 Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus Moreno, R. Rojas, L. A. Villellas, Felip Vilardell Soriano, Vanessa Cervera García-Castro, J. Fajardo, C. A. Alemany, R. Stem Cells Int Research Article Antitumor efficacy of systemically administered oncolytic adenoviruses (OAdv) is limited due to diverse factors such as liver sequestration, neutralizing interactions in blood, elimination by the immune system, and physical barriers in tumors. It is therefore of clinical relevance to improve OAdv bioavailability and tumor delivery. Among the variety of tumor-targeting strategies, the use of stem cells and specifically bone marrow-derived mesenchymal stem cells (BM-MSCs) is of particular interest due to their tumor tropism and immunomodulatory properties. Nonetheless, the invasive methods to obtain these cells, the low number of MSCs present in the bone marrow, and their restricted in vitro expansion represent major obstacles for their use in cancer treatments, pointing out the necessity to identify an alternative source of MSCs. Here, we have evaluated the use of menstrual blood-derived mesenchymal stem cells (MenSCs) as cell carriers for regional delivery of an OAdv in the tumor. Our results indicate that MenSCs can be isolated without invasive methods, they have an increased proliferation rate compared to BM-MSCs, and they can be efficiently infected with different serotype 5-based capsid-modified adenoviruses, leading to viral replication and release. In addition, our in vivo studies confirmed the tumor-homing properties of MenSCs after regional administration. Hindawi 2017 2017-07-11 /pmc/articles/PMC5525077/ /pubmed/28781596 http://dx.doi.org/10.1155/2017/3615729 Text en Copyright © 2017 R. Moreno et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Moreno, R.
Rojas, L. A.
Villellas, Felip Vilardell
Soriano, Vanessa Cervera
García-Castro, J.
Fajardo, C. A.
Alemany, R.
Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus
title Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus
title_full Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus
title_fullStr Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus
title_full_unstemmed Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus
title_short Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus
title_sort human menstrual blood-derived mesenchymal stem cells as potential cell carriers for oncolytic adenovirus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525077/
https://www.ncbi.nlm.nih.gov/pubmed/28781596
http://dx.doi.org/10.1155/2017/3615729
work_keys_str_mv AT morenor humanmenstrualbloodderivedmesenchymalstemcellsaspotentialcellcarriersforoncolyticadenovirus
AT rojasla humanmenstrualbloodderivedmesenchymalstemcellsaspotentialcellcarriersforoncolyticadenovirus
AT villellasfelipvilardell humanmenstrualbloodderivedmesenchymalstemcellsaspotentialcellcarriersforoncolyticadenovirus
AT sorianovanessacervera humanmenstrualbloodderivedmesenchymalstemcellsaspotentialcellcarriersforoncolyticadenovirus
AT garciacastroj humanmenstrualbloodderivedmesenchymalstemcellsaspotentialcellcarriersforoncolyticadenovirus
AT fajardoca humanmenstrualbloodderivedmesenchymalstemcellsaspotentialcellcarriersforoncolyticadenovirus
AT alemanyr humanmenstrualbloodderivedmesenchymalstemcellsaspotentialcellcarriersforoncolyticadenovirus